Predicting Alzheimer's Disease Progression Using Multi-modal Deep Learning Approach

Paper Link

1. Summary:

1.1 Hypothesis :

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects millions of people worldwide. Early detection and intervention are crucial for delaying the onset and severity of AD symptoms. Current available treatments decelerate only the progression of AD and no treatment developed so far can cure a patient who is already in AD. Thus, it is of fundamental importance for timely treatment and progression delay to develop strategies for detection of AD at early stages before clinical manifestation. As a result, the concept of mild cognitive impairment (MCI) was introduced. MCI, a prodromal form of AD, is defined to describe people who have mild symptoms of brain malfunction but can still perform everyday tasks.

The paper is about predicting Alzheimer's disease (AD) progression using a multi-modal deep learning approach. AD is a progressive neurodegenerative disorder that causes cognitive decline and dementia. Mild cognitive impairment (MCI) is an intermediate stage between normal aging and AD, and some MCI patients convert to AD over time. The paper aims to develop a method that can identify MCI converters from non-converters using longitudinal and cross-sectional biomarkers from multiple domains. Therefore, there is a need for developing novel and effective methods for predicting AD progression using non-invasive and multimodal biomarkers.

1.2 Contribution:

The paper proposes a multi-modal recurrent neural network (RNN) that can integrate longitudinal cognitive performance and cerebrospinal fluid (CSF) biomarkers, as well as cross-sectional neuroimaging and demographic data at baseline. The paper uses a gated recurrent unit (GRU) to process specifically a gated recurrent unit (GRU), to integrate the temporal and spatial features from each modality and to classify MCI patients into converters and non-converters. The authors evaluated their model on the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort and compared it with existing methods using single or multimodal data at baseline. The paper uses all available subjects from each modality for training the classifier, and evaluates the performance of the method using the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.

1.3 Methodology:

- The paper uses four types of data: demographic information, neuroimaging phenotypes measured by MRI, cognitive performance, and CSF measurements.
- The paper trains a single GRU for each modality separately, and then concatenates the four feature vectors produced by each GRU to form an input for the final prediction.
- The paper uses l1-regularized logistic regression for the classification between MCI converters and non-converters.
- The paper tests the classifier on MCI patients to predict the conversion after 6, 12, 18, and 24 months from baseline, and compares the performance with other methods using cross-sectional or single-modal data.



Overview of the proposed method which contains multiple GRU components that accept each modality of the dataset. At the first training step (blue dashed rectangle), each GRU component takes both time series or non-time series data to produce fixed-size feature vectors. And then the vectors are concatenated to form an input for the final prediction in the second training step (red dashed rectangle).

1.4 Conclusion:

The paper shows that the proposed method achieves the best performance with 81% accuracy and 84% sensitivity when incorporating longitudinal multi-modal data. The paper demonstrates that the proposed method can use irregular longitudinal data and non-overlapping samples from each modality effectively. The paper suggests that a

multi-modal deep learning approach has potential to identify persons at risk of developing AD who might benefit most from a clinical trial or as a stratification approach within clinical trials.

2. Limitations:

2.1 First Limitation :

Data scarcity and imbalance:

The authors acknowledged that their model suffered from the lack of positive samples (MCI converters) and the imbalance between positive and negative samples (MCI non-converters). This could affect the generalizability and robustness of their model. The authors suggested that using more data from other sources or applying data augmentation techniques could alleviate this problem.

2.2 Second Limitation :

Feature extraction and integration:

The authors noted that their model could not learn from the final prediction result to update the parameters in each GRU for feature extraction. This could limit the ability of their model to capture the features that are relevant to AD progression across multiple modalities. The authors suggested that linking the GRUs to the logistic regression in the second step or modifying the structure of their model to allow for integrative feature extraction could improve their model.

3. Synthesis:

Potential applications: The authors' model could be applied to other neurodegenerative diseases that have similar biomarkers and progression patterns as AD, such as Parkinson's disease or frontotemporal dementia. The authors' model could also be used to monitor the effects of interventions or treatments on MCI patients by tracking the changes in their biomarkers over time. The authors' model could also be integrated with other sources of information, such as genetic data or lifestyle factors, to provide a more comprehensive and personalized assessment of AD risk and prognosis.

Future scopes: The authors' model could be further improved by incorporating more advanced deep learning techniques, such as attention mechanisms or graph neural networks, to enhance the feature extraction and integration process. The authors' model could also be validated on larger and more diverse datasets, such as those from different countries or ethnicities, to test its scalability and transferability. The authors' model could also be extended to predict other outcomes or stages of AD, such as prodromal AD or dementia, or to identify subtypes or clusters of MCI patients based on their biomarker profiles.